CytRx Corporation (CYTR) Tops Q3 EPS by 3c
More News related to CYTR
- CytRx to Present at the 12th Annual BIO CEO & Investor Conference
- CytRx Announces 2010 Clinical and Development Milestones
- CytRx (CYTR) to Initiate Phase 2 Proof-of-Concept Trial to Evaluate Efficacy/Safety of Bafetinib
- CytRx to Conduct Phase 2 Clinical Trial with Bafetinib in B-cell Chronic Lymphocytic Leukemia
- Morning Movers 01/08: AEN, CYCC, SPDE, LEI, HTX, LUNA Higher; SNTA, ROG, DMAN, LWSN Lower
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
CytRx Corporation (NASDAQ: CYTR) reports Q3 EPS of $0.04, 3 cents better than estimates. Revenues were $7.0 million vs. $4.95 million consensus.
[SM]
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
